Celltrion: 투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인)
AI reading
★★★ Bullish · Material event
Keytruda biosimilar US Phase 3 clinical trial amendment approval
Key figures: 임상대상자 220명, 기간 2년
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Celltrion
- 09.23 ★★★ Zymfentra US Phase 3 clinical trial approval (rheumatoid arthritis)
- 09.23 ★★ Large Shareholding Report (General)
- 09.21 ★★★ Darzalex biosimilar EU Phase 3 clinical trial approval
- 09.16 ★★ Cancellation of treasury shares for stock price stabilization and shareholder value enhancement
- 09.07 ★★★ Darzalex biosimilar Korea Phase 3 clinical trial amendment approval
- 08.31 ★★★★ 주가 안정 및 주주가치 제고를 위한 자기주식 취득 및 전량 소각 계획
For information only. Not investment advice.